Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (730kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-527643
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.52764
Zusammenfassung
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with adverse outcomes that have barely improved over the last decade. About half of all patients present with metastasis at the time of diagnosis, and the 5-year overall survival rate across all stages is only 6%. Innovative in vivo research models are necessary to combat this cancer and to discover novel treatment strategies. ...